Investigating FGFR-targeted therapy
Discover more about urinary tract and bladder cancer
Learn about PROPEL and PROPEL 2
BridgeBio Pharma and Affiliate QED Therapeutics Announce FDA Acceptance of New Drug Application for Infigratinib for the Treatment of Cholangiocarcinoma
BridgeBio Pharma Expands Reach Into China and Other Major Asian Markets Through Strategic Collaboration With Perceptive Advisors-Founded Company, LianBio
Ivy Brain Tumor Center and BridgeBio Pharma’s QED Therapeutics Announce Dosing of First Patient in Investigator-Initiated Phase 0/2 Clinical Trial of Infigratinib in Recurrent Glioblastoma
I am an HCP and would like to someone from QED to contact me.
75 Federal Street
San Francisco, CA 94107
By selecting “Proceed” you will leave QEDTx.com and be directed to an external website.